$-0.07 EPS Expected for Organovo Holdings, Inc. (ONVO) on June, 6

May 17, 2018 - By Robert Case

Organovo Holdings, Inc. (NASDAQ:ONVO) Corporate Logo
Big Money Sentiment decreased to 0.67 in 2017 Q4. It has change of 0.86, from 2017Q3’s 1.53. The ratio turned negative due to Organovo Holdings, Inc. positioning: 16 sold and 38 reduced. 18 funds took positions and 18 increased positions. Investors holded 24.05 million in 2017Q3 but now own 20.74 million shares or 13.74% less.
Barclays Public Limited reported 15,960 shs. State Bank Of New York Mellon reported 669,508 shs. Cetera Advsr Ltd Llc holds 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO) for 15,202 shs. Citadel Advisors Ltd Liability Com stated it has 311,307 shs. Lpl Fincl Ltd Liability Com accumulated 75,981 shs. Sigma Planning accumulated 0.02% or 157,200 shs. 80,350 were accumulated by Alliancebernstein Limited Partnership. Voya Inv Mgmt Lc invested in 52,032 shs. Tortoise Invest Limited Liability Co holds 0% in Organovo Holdings, Inc. (NASDAQ:ONVO) or 360 shs. Florida-based State Board Of Administration Of Florida Retirement Systems has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Proshare Advisors Ltd Liability stated it has 14,877 shs or 0% of all its holdings. Creative Planning has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Inv House Limited Liability Com stated it has 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO). Architects stated it has 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Moreover, Parallax Volatility Advisers L P has 0% invested in Organovo Holdings, Inc. (NASDAQ:ONVO).

On June, 6 WallStreet expected Organovo Holdings, Inc. (NASDAQ:ONVO)’s earnings report, Zacks reports. Analysts expect change of 30.00 % or $0.03 from previous year’s $-0.1 earnings per share compared to current’s $-0.07 earnings per share. After $-0.07 EPS report last quarter, Wall Street now forecasts 0.00 % EPS growth of Organovo Holdings, Inc.. ONVO is hitting $1.7 during the last trading session, after decreased 2.30%.Organovo Holdings, Inc. is downtrending after having declined 67.42% since May 17, 2017. ONVO has 2.45M volume or 167.54% up from normal. ONVO underperformed by 78.97% the S&P 500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications.The firm is valued at $188.42 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners.Currently it has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were brought out by Nasdaq.com, Globenewswire.com and Globenewswire.com. The first one has “Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results” as a title and was brought out on May 14, 2018. The next is “New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals …” on May 16, 2018. And last was brought out on May 03, 2018, called “Organovo and Samsara Sciences Partner with New Manufacturing USA Institute”.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: